Image source: Getty.
Earlier this year, I named the clinical-stage cancer immunotherapy company Bellicum Pharmaceuticals (NASDAQ: BLCM) as my top biotech stock pick for 2016. Almost immediately after doing so, however, Bellicum’s shares went into free fall, shedding over half of their value: